PDS Biotechnology Corp expected to post a loss of 29 cents a share - Earnings Preview

PDS Biotechnology

24/03/2023 14:09

* PDS Biotechnology Corp  PDSB.OQ   PDSB.O  is expected
to show no
change in quarterly revenue when it reports  results on March
28. 
    * 
    * ​Refinitiv's mean analyst estimate for PDS Biotechnology
Corp is
for a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for PDS
Biotechnology
Corp is $19​, above​ its last closing price of $5.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.28       -0.28      -0.26     Beat    7.6
 Jun. 30 2022  -0.28       -0.28      -0.20     Beat    29
 Mar. 31 2022  -0.23       -0.22      -0.32     Missed  -42.9​
 Dec. 31 2021  -0.27       -0.24      -0.22     Beat    9
 ​​Sep.        -0.20       -0.20      -0.24     Missed  -17.1
 30 2021                                                
 Jun. 30 2021  -0.17       -0.17      -0.03     Beat    82.8​
 Mar. 31 2021  -0.17       -0.19      -0.14     Beat    25.3
 Dec. 31 2020  -0.18       -0.19      -0.18     Beat    3.6
 This summary was machine generated March 24 at 14:09 GMT.  All
figures in US dollars  unless otherwise stated